propyphenazone
Sign in to savethumb|Saridon (Combination drug with Propyphenazone) from Hoffmann-La Roche|Hoffman-La Roche, ca. 1950/60 Propyphenazone (known as isopropylantipyrine in Japan) is a derivative of phenazone with similar analgesic and antipyretic effects. Originally patented in 1931, propyphenazone is marketed as a combination formulation with paracetamol and caffeine for treatment of primary headache disorder.
Research
379 papers- [Propyphenazone. Pharmacology and use].Medizinische Monatsschrift fur Pharmazeuten · 2004
- Propyphenazone-induced serum sickness.International journal of dermatology · 1990
- Guideline for allergological diagnosis of drug hypersensitivity reactions: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) in cooperation with the German Dermatological Society (DDG), the Association of German Allergologists (ÄDA), the German Society for Pediatric Allergology (GPA), the German Contact Dermatitis Research Group (DKG), the German Society for Pneumology (DGP), the German Society of Otorhinolaryngology, Head and Neck Surgery, the Austrian Society of Allergology and Immunology (ÖGAI), the Austrian Society of Dermatology and Venereology (ÖGDV), the German Academy of Allergology and Environmental Medicine (DAAU), and the German Documentation Center for Severe Skin Reactions (dZh).Allergologie select · 2023
- Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone).British journal of clinical pharmacology · 1980
- Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors.ACS medicinal chemistry letters · 2014
via PubMed
Article
6 sectionsContents
- Serious adverse events
- Excerpt from WHO comments
- Banned
- Synthesis
- See also
- References
thumb|Saridon (Combination drug with Propyphenazone) from Hoffmann-La Roche|Hoffman-La Roche, ca. 1950/60 Propyphenazone (known as isopropylantipyrine in Japan) is a derivative of phenazone with similar analgesic and antipyretic effects. Originally patented in 1931, propyphenazone is marketed as a combination formulation with paracetamol and caffeine for treatment of primary headache disorder.
==Serious adverse events== Case reports have described acute inferior-wall myocardial infarctions characterized by low atrial rhythms (Kounis syndrome) secondary to propyphenazone use.